Acurx Pharmaceuticals Inc Ordinary Shares ACXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
-
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
-
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
-
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
-
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
-
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
-
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
-
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Trading Information
- Previous Close Price
- $1.26
- Day Range
- $1.25–1.30
- 52-Week Range
- $1.23–8.34
- Bid/Ask
- $1.26 / $1.29
- Shares Outstanding
- 5.56M
- Market Cap
- $5.42M
- Volume/Avg
- 64,944 / 127,578
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.acurxpharma.com
Valuation
|
Metric
|
ACXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACXP
|
|---|---|
Quick Ratio | 3.80 |
Current Ratio | 3.88 |
Interest Coverage | — |
Quick Ratio
ACXP
Profitability
|
Metric
|
ACXP
|
|---|---|
Return on Assets (Normalized) | −76.46% |
Return on Equity (Normalized) | −111.98% |
Return on Invested Capital (Normalized) | −114.93% |
Return on Assets
ACXP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#^c^Wsh | LOCK|%Sg$ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|PgHFn&< | LOCK|j&<J | $76B | |||
| Moderna Inc
MRNA
| LOCK|cK#c@L | LOCK|G%? | $75B | |||
| argenx SE ADR
ARGX
| LOCK|BB&zGtt | LOCK|Q& | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|hmRLFc! | LOCK|F# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|NM@ft? | LOCK|ZS#C | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|L%S!CsK | LOCK|^Mst | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|?>!$Bcf | LOCK|>>x | $24B | |||
| Incyte Corp
INCY
| LOCK|yRzTdz$ | LOCK|%D% | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$MV>rcD | LOCK|?!R | $15B |
United States